Access
To read this story in full you will need to login or make a payment (see right).
News
Nature Medicine 13, 392 - 393 (2007)
Published online: 28 March 2007 | doi:10.1038/nm0407-392b
Controversy over cervical cancer vaccine spurs safety surveillance
Brandon Keim1
- New York
Abstract
Scientists launch studies to address long term safety and effectiveness.
When Gardasil, the first vaccine against human papilloma virus (HPV), was approved in June 2006 by the US Food and Drug Administration, it was widely hailed as a godsend for women.Clinical trials involving more than 20,000 women showed the vaccine to be safe and effective.
To read this story in full you will need to login or make a payment (see right).
